Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583982 · ClinicalTrials.gov registry record
ImmuneSense™ COVID-19 Study
A clinical trial, sponsored by Adaptive Biotechnologies.
- Completed
- Registry status
- 180
- Enrollment target
NCT04583982: Completed study, sponsored by Adaptive Biotechnologies.
NCT04583982 is a clinical trial that has completed, run by Adaptive Biotechnologies. The registered enrollment target is 180 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04583982 has completed, sponsored by Adaptive Biotechnologies.
- COMPLETED
- Registry status
- 180 participants
- Enrollment target
Study Summary
Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred to as immunoSEQ Dx SARS-CoV-2) Assay in support of Adaptive's Emergency Use Authorization (EUA) request for T-Detect™ SARS-CoV-2 and secondary aims. This assay is intended to detect immune response to the virus that causes coronavirus disease (COVID-19), SARS-CoV-2. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot.
Primary Outcome
To demonstrate the clinical agreement of the T-Detect™ SARS-CoV-2 Assay in participants with a positive and negative result from an EUA approved RT-PCR assay.
Interventions
- OTHER T-Detect™ SARS-CoV-2 Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2020-12-04 |
What the finished NCT04583982 record still lists
NCT04583982 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which T-Detect™ SARS-CoV-2 Assay is the first listed.
NCT04583982 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04583982 about?
NCT04583982 is a clinical study titled "ImmuneSense™ COVID-19 Study". Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred to as immunoSEQ Dx SARS-CoV-2) Assay in support of Adaptive's Emergenc...
What is the current status of trial NCT04583982?
This trial is currently completed. The enrollment target is 180 participants. The study started on 2020-10-09. Estimated completion is 2020-12-04.
What interventions are being tested in trial NCT04583982?
The interventions under investigation include: T-Detect™ SARS-CoV-2 Assay (OTHER).
Who is sponsoring clinical trial NCT04583982?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI